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Abstract 
Background: Influenza is historically an ancient disease that causes annual epidemics and, at irregular intervals, 
pandemics. At present, the first-line drugs (oseltamivir and zanamivir) don’t seem to be optimistic due to the spon-
taneously arising and spreading of oseltamivir resistance among influenza virus. Pogostemon cablin (Blanco) Benth. 
(P. cablin) is an important traditional Chinese medicine herb that has been widely used for treatment on common 
cold, nausea and fever. In our previous study, we have identified an extract derived from P. cablin as a novel selective 
neuraminidase (NA) inhibitor.
Results: A series of polyphenolic compounds were isolated from P. cablin for their potential ability to inhibit neurami-
nidase of influenza A virus. Two new octaketides (1, 2), together with other twenty compounds were isolated from 
P. cablin. These compounds showed better inhibitory activity against NA. The significant potent compounds of this 
series were compounds 2 (IC50 = 3.87 ± 0.19 μ mol/ml), 11, 12, 14, 15, 19 and 20 (IC50 was in 2.12 to 3.87 μ mol/
ml), which were about fourfold to doubled less potent than zanamivir and could be used to design novel influenza 
NA inhibitors, especially compound 2, that exhibit increased activity based on these compounds. With the help of 
molecular docking, we had a preliminary understanding of the mechanism of the two new compounds (1–2)’ NA 
inhibitory activity.
Conclusions: Fractions 6 and polyphenolic compounds isolated from fractions 6 showed higher NA inhibition 
than that of the initial plant exacts. The findings of this study indicate that polyphenolic compounds and fractions 6 
derived from P. cablin are potential NA inhibitors. This work is one of the evidence that P. cablin has better inhibitory 
activity against influenza, which not only enriches the compound library of P. cablin, but also facilitates further devel-
opment and promises its therapeutic potential for the rising challenge of influenza diseases.
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Background
Influenza can cause serious public health and economic 
problems, which affects millions of people worldwide. 
Despite advances in the understanding of molecular and 
cellular aspects of influenza, the disease remains the 
major cause of mortality and morbidity among patients 
with respiratory diseases [1].
Influenza viruses have several proteins that are impli-
cated in virulence: the surface proteins hemagglutinin 
(HA) and neuraminidase (NA), the polymerase complex 
(including the PB1, PB2 and PA proteins), and the non-
structural proteins [2]. NA is an antiviral target of high 
pharmaceutical interest because of its essential role in 
cleaving sialic acid residues from cell surface glycopro-
tein and facilitating release of virions from infected cells.
The anti-influenza drugs approved for clinical use 
are the NA inhibitors (orally administered oseltamivir 
trade name Tamiflu and inhaled zanamivir trade name 
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Relenza). Both of them are sialic acid (Neu5Ac) ana-
logues. Because such inhibitors may be structurally rec-
ognized as inhibitors by the cellular NA from the host, 
this might result in side effects. Therefore, develop-
ing novel NA inhibitors to combat influenza virus is 
desirable.
Natural products, especially those derived from tra-
ditional Chinese medicine herbs (TCMH), are still the 
major source of innovative therapeutic agents for infec-
tious diseases, cancer, lipid disorders and immunomod-
ulation [3]. Pogostemon cablin is an annual herb mostly 
distributed in the tropical and subtropical regions of 
Asia. P. cablin has been recorded in Chinese Pharmaco-
poeia as a traditional herbal medicine for its therapeu-
tic functions, including eliminating heat and dampness, 
calming nerves, and alleviating fatigue. It is used in tra-
ditional Chinese medicine for the treatment of upset 
stomach, vomiting and diarrhea, headache, and fever [4]. 
Chemical and pharmacological researches on P. cablin 
have been carried out in recent years [5]. A number of 
mono- and sesquiterpenoids [6], triterpenoids and ster-
oids [7], flavonoids [8], alkaloids [9] and phenylpropanoid 
glycosides [10] have been discovered from the title plant.
P. cablin and polyphenolic compounds present in 
them have gained a lot of interest due to their beneficial 
health implications. Dietary polyphenolic compounds, 
especially phenylpropanoid glycosides, exert antioxidant 
properties and are better inhibitors of NA of influenza A 
virus [11]. In our ongoing effort to characterize new nat-
ural compounds used in Traditional Chinese Medicine 
(TCM) herbs with interesting chemical structures and/
or pharmaceutical activities, we studied on the chemical 
constituents of the aerial parts of P. cablin, which led to 
the isolation of two new octaketides (1, 2), together with 
other twenty compounds were isolated from P. cablin. 
This is the first report that presents compounds 1–9, 11 
and 21–22 in this genus.
In a previous study from our research group, several 
extracts derived from P. Cablin have better inhibitory 
activity on NA. In extending these studies, we exam-
ined the effects of these compounds against NA activity. 
According to the results obtained, the extracts exhibited 
better inhibitory activity against NA, and the polyphe-
nolic compounds presents in them are responsible for 
their biological properties. Our current results imply that 
these specific plant extracts are a possible source of new 




 Named cytosporone VI, colorless noodle-like crys-
tal with a negative optical rotation ([α]D15 −  9.5, c =  0.5, 
CHCl3). The molecular formula of compound 1 was deter-
mined as C14H18O5 from its positive mode HR-ESI MS 
data at m/z 289.1051 [M + Na]+ (calcd for C14H18O5Na, 
289.1052), which was compatible with 1H NMR and 13C 
NMR data. The 1H NMR and 13C NMR spectral data 
(Table  1) of compound 1, in combination with HSQC, 
indicated the co-existence in the molecule of two meta-
coupled aromatic methines: δH 6.29 (1H, d, J = 4 Hz), δC 
101.42 and δH 6.25 (1H, d, J = 4 Hz), δC 110.43; one car-
boxyl group: δC 172.75; and a methylene: δH 3.50 (2H), δC 
38.94, which is presumably located between the phenyl 
and carboxyl groups. Furthermore, a side chain was indi-
cated by one ketone group: δ C 211.28; two methyl groups: 
δH 0.90 (3H, t), δC 10.91 and δH 1.08 (3H, d, J = 8.5 Hz), 
δC 14.87, a methylene: δH 1.35 (1H, m), 1.75 (1H, m), δC 
25.94, and a methine: δH 3.40 (1H, m), δC 47.23. The side 
chain was determined to be 2- methylbutan-1-one by the 
1H-1H COSY and TOCSY spectra, revealing the 1H -1 H 
spin systems of H-10/H-11/H-12 and H-10/H-13, and the 
HMBC spectra correlations of H-12/C-10, H-12/C-11, 
H-13/C-9 and H-13/C-11 (Fig.  2). In conjunction with 
other key HMBC correlations of H-2/C-1, H-2/C-8, H-4/
C-2, H-6/C-4, H-6/C-8, and H-10/C-8, these observations 
suggested that compound 1 was assigned as a 5, 7-dihy-
droxy-8-(2-methylbutan-1-onyl)-ethyl phenylmethyl ester. 
This is structurally associated with cytosporone analogues. 
The absolute configuration of C-10 in the side chain was 
established as R by comparing the specific rotation value 
([α]D15 − 9.5, c = 0.5, CHCl3) for 1 to those known synthetic 
isomeric compounds, which showed a negative specific 
rotation for the R-configuration and a positive specific 
rotation for the S-configuration in the side chain of the 
related synthetic ones ((2R)-l-phenyl-2-methylbutan-l-
one, [α]D15− 36.9 and (2S)-l-phenyl-2-methylbutan-l-one, 
[α]D15 + 36.8) [12]. On the basis of above data, the structure 
of 1 was elucidated as 5, 7-dihydroxy-8-((2R)-2-methylbu-
tan-1-onyl)-methyl phenylacetate.
Compound 2:
 White amorphous powder (MeOH), the molecular for-
mula of compound 2 was determined to be C19H26O10 on 
the basis of HR-ESI MS (m/z 437.1390 [M + Na]+, calcd 
for C19H26O10Na, 437.1424) in the positive mode HR-ESI 
MS. For the 1 H NMR and 13 C NMR spectral data of com-
pound 2 see Table 1. The aglucone of compound 2 was an 
analogue compound of 1, and the HMBC spectra correla-
tion between H-1′ and C-7 confirmed the position of glu-
copyranosyl moiety. The absolute configuration of C-10 in 
the side chain was established as R for the CD spectra of 
2 (217 nm, Δε −9.49; 208 nm, Δε +5.01) which in accord-
ance with compound 1 (218 nm, Δε −15.47; 205 nm, Δε 
+9.12) (Fig. 3). On the basis of above data, the structure 
of 2 was elucidated as 5, 7-dihydroxy-8-((2R)-2-methylb-
utan-1-onyl)-phenylacetic acid 7-O-β-D-glucopyranoside.
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Fig. 1 Chemical structures of compound 1–22
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The structures of compound (7 E, 9 S)-9-Hydroxy-5, 
7-megastigmadien-4-one 9-O-β-D-glucopyranoside (5) 
and (7 E, 9 R)-9-Hydroxy-5, 7-megastigmadien-4-one 
9-O-β-D-glucopyranoside (6) [13], which were iso-
lated from P. cablin for the first time, were deduced by 
analyzing the MS, 1D, 2D NMR spectra, rotation and CD 
curves (Fig.  4). The CD curves of compounds 5 and 6 
were also firstly reported in this report.
The compounds 3, 4 and 7–22 were identified by com-
parison of their physicochemical data (NMR, MS, [α]) 
with those reported in the literature as (6 S, 7 E, 9 S)-6, 
9-Dihydroxy-4, 7-megastigmadien-3-one 9- O-β-D-
glucopyranoside (3) [14], (6 S, 7 Z, 9 R)-6, 9-Dihydroxy-4, 
7-megastigmadien -3-one 9- O-β-D-glucopyranoside (4) 
[15], and Vervenone- 10-O-β-D-glucopyranoside (7) [16], 
2- (3, 4-dihydroxyphenyl)-2-hydroxyethyl, 4- [(2E)-3- (3, 
4-dihydroxyphenyl)-2-propenoate] β- D- Glucopyra-
noside (8) [17], isocampneoside II (9), campneoside II 
(10), 4- [(2E)-3- (3, 4-dihydroxyphenyl)-2-propenoate β- 
D- Glucopyranoside (11), cistanoside F (12), descaffeoyl 
crenatoside (13) [18, 19], crenatoside (14), isocrenatoside 
(15) [20], rosmarinic acid (16), apigenin (17) [21], nepe-
tin (18), [22] isopedicularioside G (19), pedicularioside G 
(20) [23], guanosine (21) [24], 6-Hydroxy-4-(4-hydroxy-
3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-3, 
4-dihydro-2-naphthaldehyde (22) [25], respectively 
(Additional file 1). The compounds 1–9, 11, 18, 19 and 
21–22 were isolated from P. cablin for the first time.
Evaluation of NA inhibition activity
NA remains an attractive anti-influenza drug target, 
while the emergence of viruses resistant to currently 
available drugs has presented a new challenge. Therefore, 
compounds 1–22 and fractions 1–7 (Fig. 5) were tested 
for their inhibitory effects against the influenza virus 
NA in vitro with the commercial NA inhibitory screen-
ing kit. Even though a number of biological activity stud-
ies on this plant have been performed, so far only a few 
anti-influenza virus constituents from P. cablin have been 
reported. In this study, the half inhibitory concentration 
(IC50) of compounds 1–22 were evaluated for their inhib-
itory effects against the influenza virus NA in vitro as a 
screening system. The NA inhibitory activity experiment 
results are shown in Tables 2 and 3 (Additional file 2).
Good oral availability can be achieved by right bal-
ance between partitioning and solubility properties. To 
understand the properties of the proposed compounds 
better, we utilized Molinspiration [26] to predict some 
properties of the typical compounds (1, 2, 16, 20 and 22) 
(Table  4), and applied the Lipinski’s rule of five [27] to 
see whether all passed the criteria. Lipinski’s rule of five 
acts as a filter for drug like properties and states that a 
potential molecule is orally active if it’s molecular weight 
is ⩽500 da, log P ⩽5, number of hydrogen bond accep-
tors ⩽10, number of hydrogen bond donors ⩽5. Under 
the Lipinski’s rule of five, compounds (1, 2, 16, 20 and 
22) presenting mi log P (< 5) suggested that they may all 
have good oral bioavailability, and compounds 1 and 22 
Table 1 1H (500 MHz) and 13C (125 MHz) NMR spectral data 
of compounds 1 and 2
a Measured in CD3OD
b Measured in DMSO-d6, δ Chemical shifts are given in ppm, J values are in 
parentheses and reported in Hz
Position 1a 2b
δC δH δC δH
1 172.75 172.08




6 101.42 6.29, d (4) 100.86 6.49, br s
7 159.95 159.59
8 110.43 6.25, d (4) 112.28 6.37, br s
9 211.28 209.76
10 47.23 3.40, m 47.44 3.25




12 10.91 0.90, t 11.90 0.82, t
13 14.87 1.08, d (8.5) 15.76 0.98, d (6.5)
14-OCH3 51.02 3.68, s


















Fig. 2 Key HMBCs (→) and 1H-1H COSY (bold) correlations of com-
pound 1–2
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might be two lead compounds for anti-influenza. (mi log 
P: logarithm of compound partition coefficient between 
n-octanol and water).
Molecular docking studies
Earlier crystallographic and ensuing SAR studies have 
revealed that the active site of NA could be divided into 
four major binding sites [28]. All NA inhibitors on the 
market or in clinical phases possess strong structural 
resemblance in those parts, which correspond to the fact 
that the four pockets are critical for interaction with the 
active site of NA.
The pocket C1 is comprised of positively charged guan-
idino groups of arginines 118, 292 and 371 and interacts 
with the carboxylate. In pocket C5, Arg 152 functions as 
the hydrogen-bond donor. Trp 178 and Ile 222 comprise 
a small hydrophobic region. In pocket C4, usually a guan-
idine or an amine group participates in charge–charge 
interactions and hydrogen bonds to Glu 119, Asp 151, 
and/or Glu 227. In pocket C6, Glu 276, the side chain 
of Arg 152, the amidic carbonyl of Trp 178 and Asp 151 
form a new hydrophobic binding pocket. Moreover, Glu 
277 and Tyr 406 are believed to play a critical role in the 
catalytic activity of NA [29, 30].
From the activity assay results, compounds 1 and 2 
showed better inhibitory activities against NA. To pro-
vide a further insight on the observed activities, the 
binding of compounds 1 and 2 in the active site of NA is 
shown in Fig. 6. we find that the-COOH group of com-
pound 2 interacts with the pocket C4 of NA active site 
by hydrogen bond with Glu 119 of this subsite, anomeric 
carbon of glucose binds to the pocket C4 by hydrogen 
bond interaction with Asp 151, and 5-OH group forms 
hydrogen bond with Glu 227 of pocket C4.
Moreover, for compound 1, the 7-OH group binds to 
the pocket C6 by hydrogen bond interaction with Glu 
277, the 1-CO-group forms a hydrogen bond with Arg 
152 and Arg 292 of pocket C1, and the 5-OH group binds 
to the pocket C4 by hydrogen bond interaction with 
Asp151 (Fig. 7).
Fig. 3 The CD curves of compounds 1 and 2
Fig. 4 The CD curves of compounds 5 and 6
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The binding of compound 1 in the active site of NA 
showed that the three pockets (C1, C4, C6) of the active 
site of NA were occupied, although not so well as zan-
amivir, but still can be a lead compound.
Methods
General information
Optical rotations were recorded on a Jasco P-2000 auto-
matic digital polarimeter. The 1 H NMR, 13C NMR, 1H-1H 
Fig. 5 Process for the separation of compounds 1–22
Table 2 NA inhibition activity of compounds 1–22
Zanamivir was the positive control; each value represents the mean ± SD (n = 3)
Compound IC50 (μ mol/ml) Compound IC50 (μ mol/ml) Compound IC50 (μ mol/ml)
1 8.40 ± 1.20 9 6.08 ± 0.20 17 4.69 ± 0.29
2 3.87 ± 0.19 10 6.53 ± 0.38 18 3.29 ± 0.04
3 11.62 ± 0.48 11 3.60 ± 0.02 19 2.74 ± 0.03
4 10.99 ± 1.15 12 2.99 ± 0.12 20 2.12 ± 0.04
5 10.93 ± 0.48 13 7.87 ± 0.13 21 32.67 ± 4.73
6 19.94 ± 1.95 14 3.30 ± 0.12 22 4.70 ± 0.05
7 >200 15 3.64 ± 0.17
8 6.32 ± 0.38 16 2.27 ± 0.09 Zanamivir 0.93 ± 0.02
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COSY, HSQC and HMBC spectra were recorded on a 
Bruker AM 500 spectrometer with TMS as the internal 
standard at 500 MHz and 125 MHz for 1 H and 13 C. The 
enzyme activity inhibition assay was carried out on a 
microplate spectrophotometer (Gemini EM; Molecular 
Devices). Circular dichroism (CD) spectra were recorded 
on a CD spectrometer (JASCO, J-815-150S, Japan). 
Optical rotations were recorded on an automatic digi-
tal polarimeter (Shenguang SGW-3, China). Preparative 
HPLC: Agilent 1100 Series HPLC system, a reverse-phase 
C18 column (YMC-Pack ODS-A, 250*20  mm, 5  μm, 
YMC Co., Ltd, Kyoto, Japan). Column chromatography 
was performed with Diaion HP20 (Mitsubishi, Japan) and 
Sephadex LH-20 (Pharmacia (GE)). TLC was carried out 
on precoated silica gel GF 254 plates (Qingdao Haiyang 
Chemical Co. Ltd), and spots were visualized under UV 
light (254 or 365 nm) or detected by spraying with 10 % 
H2SO4 in EtOH followed by heating.
Plant material
The aerial part of P. cablin was purchased from Suixi 
county, Guangdong province, China, in September 2014. 
The botanical identification was made by Associate Prof. 
Jin-ping Li. A voucher specimen (NO.GHX140918) 
was deposited in College of Pharmacy, Central South 
University.
Table 3 NA inhibition activity of fraction 1–7
Each value represents the mean ± SD (n = 3)
Fractions Inhibition rate % (1 mg/ml, DMSO)
1 44.71 ± 1.53
2 35.71 ± 1.15
3 69.70 ± 1.16
4 20.05 ± 1.00
5 26.38 ± 0.58
6 90.69 ± 1.53
7 18.72 ± 0.58
Table 4 Theoretical prediction of properties of compounds 1, 2, 16, 20 and 22
mi log P logarithm of compound partition coefficient between n-octanol and water; TPSA topological polar surface area; MW molecular weight; nON number of 
hydrogen bond acceptors; nOHNH number of hydrogen bond donors; Nrotb number of rotatable bonds
Compound mi log P TPSA MW nON nOHNH nviolations Volume nrotb
1 2.49 83.83 266.29 5 2 0 247.15 6
2 −0.38 173.98 414.41 10 6 1 361.74 8
16 1.63 144.52 360.32 8 5 0 303.54 7
20 −0.45 245.29 624.59 15 9 3 532.50 11
22 2.01 96.22 356.37 6 3 0 316.61 5
Fig. 6 Molecular models of compounds 1 and 2 binding to active site of NA
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Extraction and isolation
Dried powdered P. Cablin (2.0  kg) was extracted with 
water (20 L ×  3, 1  h each time) by reflux. The extracts 
were then concentrated under vacuum to afford a crude 
extract (165  g), which was suspended in H2O and suc-
cessively partitioned with EtOAc and BuOH, yielding 
32  g of EtOAc—soluble extract, 56  g of BuOH-soluble 
extract and 71  g of H2O-soluble extract. BuOH—Solu-
ble extract (56 g) was applied to a Diaion HP20 column 
(10 × 200 cm) with a step gradient elution of EtOH-H2O 
(v/v 0:1, 4:6, 9.5:0.5) to provide three factions: A1, A2 
and A3. A2 (31  g) was chromatographed over a Sepha-
dex LH-20 column (6 × 250 cm) eluted with H2O-MeOH 
system (8:2, 5:5, 0:10) to give B1–B10.
B2 (300  mg) was chromatographed on a Sepha-
dex LH-20 column (2 ×  150  cm) eluted with MeOH to 
yield B2-1, then B2-1 on a Sephadex LH-20 column 
(2  ×  90  cm) CH2Cl2-MeOH system (8:2) to give com-
pound 1 (11 mg, TLC: CH2Cl2-MeOH 10-0.1, Rf = 0.3).
B3 was chromatographed on a Sephadex LH-20 col-
umn (2 ×  150 cm) eluted with MeOH system and then 
was purified by preparative reverse-phase HPLC eluted 
with 40 % MeOH/H2O (+0.2 % formic acid (FA)) to give 
compound 15 (7  mg, tR  =  23  min) and compound 16 
(8 mg, tR = 19 min).
B4 was chromatographed on a Sephadex LH-20 column 
(2 × 150 cm) eluted with MeOH system, and then five frac-
tions (D1–D5) were got. D2 was on a Sephadex LH-20 col-
umn (2 × 150 cm) eluted with MeOH system to give two 
fractions D2-1 and D2-2, then D2-1 and D2-2 were chro-
matographed on a Sephadex LH-20 column (2 ×  90  cm) 
eluted with CH2Cl2-MeOH system (8:2) to give compound 
Fig. 7 Detailed view of the docking results of compounds 1 and 2 in the active site of neuraminidase (PDB ID: 2HU4). The Sky blue lines and num-
bers show the potential hydrogen bonds and bond length. The first one is compound 1, and the second one is compound 2
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11 (8 mg) and compound 12 (9 mg). D3 eluted with MeOH 
was purified by a Sephadex LH-20 column (2 × 150 cm), 
and then to give three fractions: D3-1, D3-2 and D3-3. D3-1 
was purified by a Sephadex LH-20 column (2  ×  90  cm) 
eluted with CH2Cl2-MeOH system (1:1) and then was puri-
fied by preparative reverse-phase HPLC eluted with 15 % 
MeCN/H2O (+0.2  % FA) to give compound 13 (7  mg, 
tR = 16.5 min). D3-3 was purified by a Sephadex LH-20 col-
umn (2 × 90 cm) eluted with MeOH and then eluted with 
CH2Cl2-MeOH system (1:1) and purified by a Sephadex 
LH-20 column (2 × 150 cm) to give compound 2 (21 mg, 
TLC: EtOAc-FA-H2O: 10-1-1, Rf = 0.4).
B5 (1.1 g) was chromatographed on a Sephadex LH-20 
column (2 × 150 cm) eluted with CH2Cl2-MeOH system 
(5:5) to give C1–C8, C3 (107 mg) chromatographed on a 
Sephadex LH-20 column (2 ×  90 cm) eluted with H2O-
MeOH system (5:5) to yield three fractions: C3-1 (36 mg), 
C3-2 (26  mg), C3-3 (50  mg). C3-1 was subsequently 
purified by preparative reverse-phase HPLC eluted 
with 11  % MeCN/H2O (+0.2  % FA) to give compounds 
3 (9 mg, tR = 18.5 min), 4 (13 mg, tR = 20.5 min), C3-3 
was subsequently purified by preparative reverse-phase 
HPLC eluted with 14 % MeCN/H2O (+0.2 % FA) to give 
7 (12 mg, tR = 27.5 min). C4 (98 mg) was subsequently 
purified by a Sephadex LH-20 column (2 × 90 cm) eluted 
with H2O-MeOH system (5:5) to yield one fraction: C4-1 
(33  mg). C4-1 was subsequently purified by prepara-
tive reverse-phase HPLC eluted with 12  % MeCN/H2O 
(+0.2 % FA) to give compound 5 (8 mg, tR = 25.5 min) 
and 6 (16 mg, tR = 26.5 min).
B6 eluted with MeOH was purified by a Sephadex 
LH-20 column (4  ×  150  cm), to yield five fractions: 
E1–E5. E2 was purified by preparative reverse-phase 
HPLC eluted with 17  % MeCN/H2O (+0.2  % FA) to 
give compound 11 (tR  =  16.5  min) and compound 10 
(tR = 23.5 min), then compounds 10 and 9 were purified 
by a Sephadex LH-20 column (2  ×  40  cm) eluted with 
MeOH system to give compounds 10 (7 mg) and 9 (9 mg), 
respectively. E3 was purified by preparative reverse-phase 
HPLC eluted with 18 % MeCN/H2O (+0.2 % FA) to give 
compounds 14 (tR = 26.5 min) and 8 (tR = 30.5 min), and 
then compounds 14 and 8 were purified by a Sephadex 
LH-20 column (2 × 40 cm) eluted with MeOH system to 
give compounds 14 (8 mg) and 8 (6.5 mg), respectively. 
E4 was chromatographed on a Sephadex LH-20 column 
(2 × 150 cm) eluted with MeOH system to give E4-1 and 
E4-2, E4-2 was purified by preparative reverse-phase 
HPLC eluted with 37 % MeOH/H2O (+0.2 % FA) to give 
compound 18 (7  mg, tR =  29  min) and E4-1 was chro-
matographed on a Sephadex LH-20 column (2 × 150 cm) 
eluted with MeOH system to give compound 22 (10 mg).
B7 was purified with a Sephadex LH-20 column 
(2 ×  150 cm) eluted with MeOH system, and then four 
fractions (B7-1, B7-2, B7-3 and B7-4) were got. B7-2 
was prepared on reverse-phase HPLC eluted with 41  % 
MeOH/H2O (+0.2  % FA) to give compound 19 (7  mg, 
tR = 21 min), B7-3 was prepared on reverse-phase HPLC 
eluted with 35 % MeOH/H2O (+0.2 % FA) to give com-
pound 20 (7 mg, tR = 20 min).
B8 was chromatographed on a Sephadex LH-20 col-
umn (2 ×  150 cm) eluted with MeOH system and then 
was purified by preparative reverse-phase HPLC eluted 
with 50 % MeOH/H2O (+0.2 % FA) to give compound 17 
(6 mg, tR = 31 min).
B9 was chromatographed on a Sephadex LH-20 col-
umn (2 ×  150 cm) eluted with MeOH system and then 
was purified by preparative reverse-phase HPLC eluted 





Colorless noodle-like crystal, C14H18O5, [α]D15  −  9.5° 
(c 0.5, CHCl3), HR-ESI MS (positive ion mode) m/z: 
289.1051 [M + Na]+ (calcd. for C14H18O5Na, 289.1052). 





White amorphous powder (MeOH), C19H26O10, HR-
ESI MS (positive ion mode) m/z: 437.1390 [M  +  Na]+ 
(calcd. for C19H26O10Na, 437.1424). 1H (500 M, DMSO-
d6) and 13C (125 MHz, DMSO-d6) NMR data, see Table 1.
Neuraminidase inhibition activity
NA inhibitory activity was determined by the com-
mercial NA inhibitory screening kit (P0309, Beyotime 
Institute of Biotechnology, Jiangsu, China). The com-
pound 2’-(4-methylumbelliferyl)-a-D-acetylneuraminic 
acid (MUNANA) is the substrate of NA. And cleavage 
of this substrate by NA produces a fluorescent product, 
322 nm was the excitation wavelength and 450 nm was 
the emission wavelength. The intensity of fluorescence 
can reflect the activity of NA sensitively. The IC50 was 
calculated by plotting percent inhibition versus the 
inhibitor concentration and determination of each point 
was performed in duplicate. The actual and detailed 
experimental which was prepared according to litera-
ture method [31].
The inhibition rates were calculated as follows: 
[A1–A(background)-[A2–A(background)]/[A1–A (back-
ground)] × 100], where A1 is the absorbance of the con-
trol, and A2 is the absorbance of the sample. IC50 was 
determined by plotting the percentage of NA activity 
against inhibitor concentration using software that came 
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with the microplate reader. The values are expressed as 
the mean ± SD of triplicate experiments.
Molecular docking
The cocrystal complex of N1 NA in complex with corre-
sponding ligand oseltamivir downloaded from the protein 
data bank. (PDB ID code 2HU4) [32]. Before docking, the 
pre-existing ligand was removed out and hydrogen atoms 
and charges were added. The docking studies were per-
formed using the Surflex-Dock module of Sybyl 8.1, and 
the maximum number of poses per ligand was set to 10. 
The active site of the protein was automatically explored 
and created based on the previous ligand oseltamivir by 
the Surflex-Dock Protomol Generation Programme, and 
other parameters were set as default.
Conclusions
The two new compounds (1, 2) and compounds 11, 12, 14, 
15, 19 and 20 showed better inhibitory activity against NA 
in  vitro. By comparing with the structures of compound 
11, 12, 14, 15, 19 and 20, they all have one caffeoyl, and 
this is a possible reason that these compounds have bet-
ter inhibitory activity against NA than other polyphenolic 
compounds. With the help of molecular docking, we had 
a preliminary understanding of the mechanism of the two 
new compounds (1–2)′ NA inhibitory activity. According 
to the Lipinski’s rule of five, compound 1 may be a better 
lead compound for anti- influenza.
Fractions 6 and polyphenolic compounds isolated from 
fractions 6 showed higher NA inhibition than that of 
the initial plant exacts (Tables 2, 3). The findings of this 
study indicate that polyphenolic compounds and frac-
tions 6 derived from P. cablin are potential NA inhibitors. 
This work was one of the evidence that P. cablin has bet-
ter inhibitory activity against influenza, which not only 
enriches the compound library of P. cablin, but also facili-
tates further development and promises its therapeutic 
potential for the rising challenge of influenza diseases.
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